Pfizer Inc. (NYSE:PFE) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,666,245 shares of the biopharmaceutical company's stock after buying an additional 1,855,419 shares during the period. Geode Capital Management LLC owned about 2.08% of Pfizer worth $3,392,342,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. M&G Plc raised its position in Pfizer by 14.5% in the 2nd quarter. M&G Plc now owns 813,423 shares of the biopharmaceutical company's stock valued at $22,776,000 after purchasing an additional 103,254 shares in the last quarter. Maia Wealth LLC acquired a new position in Pfizer during the 2nd quarter worth approximately $372,000. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Pfizer by 1.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 1,648,811 shares of the biopharmaceutical company's stock valued at $46,134,000 after purchasing an additional 21,970 shares in the last quarter. Great Valley Advisor Group Inc. lifted its position in shares of Pfizer by 6.1% during the 2nd quarter. Great Valley Advisor Group Inc. now owns 192,028 shares of the biopharmaceutical company's stock worth $5,373,000 after purchasing an additional 10,993 shares during the last quarter. Finally, ORG Partners LLC grew its stake in shares of Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company's stock worth $1,327,000 after purchasing an additional 44,458 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Bank of America restated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday. Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday, November 15th. They set an "underperform" rating and a $25.00 price target on the stock. Evercore ISI raised Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Finally, StockNews.com downgraded Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $32.64.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock traded down $0.52 during trading hours on Tuesday, reaching $25.58. 43,170,316 shares of the company's stock were exchanged, compared to its average volume of 38,526,891. The company's 50 day moving average is $27.42 and its two-hundred day moving average is $28.36. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a market cap of $144.96 billion, a P/E ratio of 34.55, a price-to-earnings-growth ratio of 0.70 and a beta of 0.65. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 8th were given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.57%. The ex-dividend date of this dividend was Friday, November 8th. Pfizer's dividend payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.